View Drug-Resistant TB—A Visual Tour
Volunteer for NIAID-funded clinical studies related to tuberculosis on ClinicalTrials.gov.
The emergence of multidrug-resistant (MDR) TB and, more recently, extensively drug-resistant (XDR) TB has intensified the need for new TB drugs. Helping discover and develop those drugs is a top NIAID priority. The Institute supports research to elucidate the mechanisms of drug resistance, identify new TB drug targets and candidate drugs, and evaluate novel TB drugs and optimal drug combinations in preclinical and clinical studies.
Important advances in TB treatment research include:
Last Updated May 13, 2010